ArticleAmerican journal of ophthalmology case reports2023
Hydrus Microstent implantation with OMNI Surgical System Ab interno canaloplasty for the management of open-angle glaucoma in phakic patients refractory to medical therapy.
Article in American journal of ophthalmology case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06953349 (Real-World Efficacy of Hydrus Microstent With OMNI Surgical System in Combination With Phacoemulsification), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-World Efficacy of Hydrus Microstent With OMNI Surgical System in Combination With Phacoemulsification: a Retrospective Analysis
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Effectiveness and Safety of Combined Ab-Interno Canaloplasty and Microstent Implantation in Severe Glaucoma - A Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Visual Function After Schlemm's Canal-Based MIGS.Journal of clinical medicine · 2025Review
- An Emerging Multi-mechanism and Multi-modal Approach in Interventional Glaucoma Therapy.Ophthalmology and therapy · 2025Article
- Standalone Canaloplasty and Trabeculotomy Using the OMNI Surgical System: A Subgroup Analysis from the American Academy of Ophthalmology IRISClinical ophthalmology (Auckland, N.Z.) · 2025Article
- Historical and Contemporary Debates in Schlemm's Canal-Based MIGS.Journal of clinical medicine · 2024Review
- A Review of Canaloplasty in the Treatment and Management of Glaucoma.Journal of current glaucoma practiceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report a series of 8 phakic eyes of 8 patients with open angle glaucoma with uncontrolled intraocular pressure on maximum tolerable medical therapy receiving Hydrus Microstent implants combined with concomitant OMNI Surgical System ab interno canaloplasty. Observations: 8 phakic eyes underwent Hydrus Microstent implantation with OMNI Surgical System ab interno canaloplasty. 2 patients underwent concurrent Kahook Dual Blade goniotomy and 1 patient underwent a concurrent micropulse transscleral cyclophotocoagulation. 6 out of 8 eyes achieved successful intraocular pressure reduction. Only 1 achieved success without the need for additional medical therapy. 1 required Neodymium-doped yttrium aluminum garnet laser to clear iris obstruction of the Hydrus inlet and 1 required selective laser trabeculoplasty for additional intraocular pressure lowering. 2 out of 8 eyes required subsequent incisional glaucoma surgery for unacceptable intraocular pressure levels despite maximum tolerable medical therapy. Conclusions and Importance: The Hydrus Microstent combined with OMNI Surgical System ab interno canaloplasty can safely and successfully reduce intraocular pressure in phakic patients with open-angle glaucoma with uncontrolled intraocular pressure on maximum tolerable medical therapy with a low complication rate and rapid visual recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.